It's Time to Test an Anti-Aging Drug Against Alzheimer's (1 of 1) (IMAGE)

American Association for the Advancement of Science (AAAS)

It's Time to Test an Anti-Aging Drug Against Alzheimer's (1 of 1)

Caption

The hallmarks of aging, such as mitochondrial dysfunction and telomere attrition, contribute to an increased risk of Alzheimer's disease and other neurological conditions. Rapamycin and other interventions that influence MTOR activity could help delay the progression of these diseases and preserve brain function in the elderly. This material relates to a paper that appeared in the Jan. 23, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by M. Kaeberlein at University of Washington in Seattle, WA; and colleagues was titled, "Rapamycin and Alzheimer's disease: Time for a clinical trial?"

Credit

M. Kaeberlein <i>et al., Science Translational Medicine</i> (2018)

Usage Restrictions

Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.